A Budget Impact Analysis of the VENTANA PD-L1 SP142 Immunohistochemistry Assay Versus the Dako PD-L1 IHC 22C3 Assay in Patients With Advanced or Metastatic Triple-Negative Breast Cancer Treated With Atezolizumab in Combination With Nab-Paclitaxel. FE [Internet]. 2021 Jul. 26 [cited 2025 Oct. 29];22(1). Available from: https://journals.seedstm.com/index.php/FE/article/view/1502